Skip to main content
OpenTrials
Completed

NCT Number: NCT06031779

Application of Serum Bile Acid Profile in the Diagnosis of Gastric Cancer

In this study, the composition and level of serum bile acids in patients with gastric cancer and non-gastric cancer were analyzed by detecting the serum bile acid profile, so as to develop new serological diagnostic methods for early diagnosis and treatment of gastric cancer.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Xijing Hosipital of Digestive Disease

Xi'an, Shaanxi, 710032, China

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age between 18-70, both gender;
  • The gastric cancer group was early gastric cancer or advanced gastric cancer diagnosed by endoscopic examination and pathological biopsy. The non-gastric cancer group included patients without gastric lesions, superficial gastritis, chronic atrophic gastritis, intestinal metaplasia or dysplasia diagnosed by gastroscopy or pathological biopsy;
  • Informed consent was obtained.

Exclusion criteria

  • The patients have diseases that affect bile acid metabolism, such as liver cirrhosis, gallstones or inflammatory bowel disease, Behcet's disease, etc;
  • Due to other diseases, the patient took drugs affecting bile acid metabolism, such as cholestyramine, anti-inflammatory Lidan tablets, Danshu capsules, ursodeoxycholic acid, obticholic acid, Schisandrin B, tanshinone ⅡA, Yinzhihuang, etc;
  • Pregnant women;
  • Primary tumors of other systems were diagnosed;
  • Those with poor physiopathological conditions, such as chronic kidney disease requiring long-term dialysis;
  • Patients with mental illness;
  • Patients who have received radiotherapy or surgery previously;
  • Those with poor adherence or difficult to follow up.

Treatment and study plan

Primary outcomes

  1. serum bile acid profile before treatment

    Time frame: 1 month

Secondary outcomes

  1. concentration of serum tumor markers before treatment

    Time frame: 1 month

    CEA, CA19-9 and CA12-5

Sponsors and collaborators

Lead sponsor

Xijing Hospital of Digestive Diseases

Other

Registry information

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Sep 11, 2023
Registry last updated
Jul 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.